Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the
treatment landscape of locally advanced esophageal squamous cell carcinoma. However, there
are still a significant proportion of patients who could not benefit from such treatment
modality. Currently, no effective biomarkers were identified to stratify responders and
non-responders. Early dynamic and persistent relief of dysphagia may act as a predictive
biomarker to reflect the on-treatment anti-tumor activity. In this prospective study, we
aimed to explore the feasibility of using patient-reported outcomes (PROs) to predict the
pathological complete response of esophageal squamous cell carcinoma patients treated with
neoadjuvant immunochemotherapy with or without short-term radiation as well as to assess the
efficacy and safety of short-term radiotherapy in PROs-insensitive patients after one cycle
of neoadjuvant immunochemotherapy.